Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | ALDH5A1 | P51649 | 1/20 | 0.35 |
| ▸ | ABAT | P80404 | 1/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.32 |
| ▸ | SRC | P12931 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
| ▸ | CA6 | P23280 | 1/20 | 0.32 |
| ▸ | CA5A | P35218 | 1/20 | 0.32 |
| ▸ | CA7 | P43166 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1619086 | 0.95 | KDM4E (0.58) | KDM4EPTGS2RAB9AALDH5A1ABAT | |
| SCHEMBL1072576 | 0.84 | KDM4E (0.48) | KDM4EPTGS2RAB9AENPP2SRC | |
| SCHEMBL1771343 | 0.84 | KDM4E (0.48) | KDM4EPTGS2RAB9AENPP2 | |
| SCHEMBL9301841 | 0.84 | KDM4E (0.48) | KDM4EPTGS2RAB9AENPP2 | |
| SCHEMBL4655558 | 0.84 | KDM4E (0.48) | KDM4EPTGS2RAB9AENPP2 | |
| Hydrochloric Acid SCHEMBL4652877 | 0.83 | KDM4E (0.47) | KDM4EENPP2 | |
| SCHEMBL14186117 | 0.81 | ENPP2 (0.46) | KDM4EENPP2 | |
| SCHEMBL29700460 | 0.80 | MGLL (0.47) | KDM4E | |
| SCHEMBL21854599 | 0.80 | MGLL (0.47) | KDM4E | |
| SCHEMBL4955182 | 0.78 | KDM4E (0.42) | KDM4EALDH5A1ABATTTRXDH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024604-A1 | NOVEL INSULIN DERIVATIVES | NOVO NORDISK AS (DK) | 2021-01-28 | — | — | US | disclosed |
| WO-2016179568-A1 | GLUCOSE RESPONSIVE INSULINS | PROTOMER TECHNOLOGIES, INC. (US) | 2016-11-10 | — | — | WO | disclosed |
| US-20120184487-A1 | INSULIN DERIVATIVES | NOVO NORDISK A/S (DK) | 2012-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024604-A1 | NOVEL INSULIN DERIVATIVES | GPR119, INSR, IRS1 | KDM4E 4401/4885PTGS2 4410/4885RAB9A 2605/4885 |
| US-20120184487-A1 | INSULIN DERIVATIVES | INSR, IRS1, GPR119 | KDM4E 4480/4885PTGS2 4476/4885RAB9A 3215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.